Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
iScience ; 25(12): 105626, 2022 Dec 22.
Article in English | MEDLINE | ID: mdl-36471805

ABSTRACT

Tumors with BRCA1 mutations have poor prognoses due to genomic instability. Yet this genomic instability has risks and BRCA1-deficient (def) cancer cells must develop pathways to mitigate these risks. One such risk is the accumulation of unfolded proteins in BRCA1-def cancers from increased mutations due to their loss of genomic integrity. Little is known about how BRCA1-def cancers survive their genomic instability. Here we show that BRCA1 is an E3 ligase in the endoplasmic reticulum (ER) that targets the unfolded protein response (UPR) stress sensors, Eukaryotic Translation Initiation Factor 2-alpha Kinase 3 (PERK) and Serine/Threonine-Protein Kinase/Endoribonuclease Inositol-Requiring Enzyme 1 (IRE1) for ubiquitination and subsequent proteasome-mediated degradation. When BRCA1 is mutated or depleted, both PERK and IRE1 protein levels are increased, resulting in a constitutively activated UPR. Furthermore, the inhibition of protein folding or UPR signaling markedly decreases the overall survival of BRCA1-def cancer cells. Our findings define a mechanism used by the BRCA1-def cancer cells to survive their increased unfolded protein burden which can be used to develop new therapeutic strategies to treat these cancers.

2.
Breast Cancer Res ; 19(1): 122, 2017 Nov 16.
Article in English | MEDLINE | ID: mdl-29145865

ABSTRACT

BACKGROUND: Proper repair and restart of stressed replication forks requires intact homologous recombination (HR). HR at stressed replication forks can be initiated by the 5' endonuclease EEPD1, which cleaves the stalled replication fork. Inherited or acquired defects in HR, such as mutations in breast cancer susceptibility protein-1 (BRCA1) or BRCA2, predispose to cancer, including breast and ovarian cancers. In order for these HR-deficient tumor cells to proliferate, they become addicted to a bypass replication fork repair pathway mediated by radiation repair protein 52 (RAD52). Depleting RAD52 can cause synthetic lethality in BRCA1/2 mutant cancers by an unknown molecular mechanism. METHODS: We hypothesized that cleavage of stressed replication forks by EEPD1 generates a fork repair intermediate that is toxic when HR-deficient cells cannot complete repair with the RAD52 bypass pathway. To test this hypothesis, we applied cell survival assays, immunofluorescence staining, DNA fiber and western blot analyses to look at the correlation between cell survival and genome integrity in control, EEPD1, RAD52 and EEPD1/RAD52 co-depletion BRCA1-deficient breast cancer cells. RESULTS: Our data show that depletion of EEPD1 suppresses synthetic lethality, genome instability, mitotic catastrophe, and hypersensitivity to stress of replication of RAD52-depleted, BRCA1 mutant breast cancer cells. Without HR and the RAD52-dependent backup pathway, the BRCA1 mutant cancer cells depleted of EEPD1 skew to the alternative non-homologous end-joining DNA repair pathway for survival. CONCLUSION: This study indicates that the mechanism of synthetic lethality in RAD52-depleted BRCA1 mutant cancer cells depends on the endonuclease EEPD1. The data imply that EEPD1 cleavage of stressed replication forks may result in a toxic intermediate when replication fork repair cannot be completed.


Subject(s)
BRCA1 Protein/genetics , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Endodeoxyribonucleases/metabolism , Rad52 DNA Repair and Recombination Protein/genetics , Synthetic Lethal Mutations , BRCA1 Protein/deficiency , Cell Line, Tumor , Cell Survival/genetics , DNA Breaks , DNA Repair , DNA Replication , Female , Gene Knockout Techniques , Genomic Instability , Homologous Recombination , Humans , Rad52 DNA Repair and Recombination Protein/metabolism
3.
Stem Cells Dev ; 26(2): 91-101, 2017 01 15.
Article in English | MEDLINE | ID: mdl-27832737

ABSTRACT

Endothelial progenitor cells/endothelial cells (EPCs/ECs) have great potential to treat pathological conditions such as cardiac infarction, muscle ischemia, and bone fractures, but isolation of EPC/ECs from existing cell sources is challenging due to their low EC frequency. We have isolated endothelial progenitor (EP)-like cells from rat oral mucosa and characterized their yield, immunophenotype, growth, and in vivo angiogenic potential. The frequency of EP-like cells derived from oral mucosa is thousands of folds higher than EPCs derived from donor-match bone marrow samples. EP-like cells from oral mucosa were positive for EC markers CD31, VE-Cadherin, and VEGFR2. Oral mucosa-derived EP-like cells displayed robust uptake of acetylated low-density lipoprotein and formed stable capillary networks in Matrigel. Subcutaneously implanted oral mucosa-derived EP-like cells anastomosed with host blood vessels, implicating their ability to elicit angiogenesis. Similar to endothelial colony-forming cells, EP-like cells from oral mucosa have a significantly higher proliferative rate than human umbilical vein endothelial cells. These findings identify a putative EPC source that is easily accessible in the oral cavity, potentially from discarded tissue specimens, and yet with robust yield and potency for angiogenesis in tissue and organ regeneration.


Subject(s)
Endothelial Cells/cytology , Mouth Mucosa/cytology , Neovascularization, Physiologic , Regeneration , Animals , Aorta/cytology , Bone Marrow Cells/cytology , Bone Marrow Cells/drug effects , Cell Count , Cell Proliferation/drug effects , Cell Separation , Collagen/pharmacology , Drug Combinations , Endothelial Cells/drug effects , Female , Flow Cytometry , Human Umbilical Vein Endothelial Cells/cytology , Human Umbilical Vein Endothelial Cells/drug effects , Kinetics , Laminin/pharmacology , Mice, Nude , Neovascularization, Physiologic/drug effects , Proteoglycans/pharmacology , Rats, Sprague-Dawley , Rats, Transgenic , Regeneration/drug effects
4.
Exp Hematol ; 38(8): 629-640.e1, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20399246

ABSTRACT

OBJECTIVE: The transcription factor PU.1 (encoded by Sfpi1) promotes myeloid differentiation, but it is unclear what downstream genes are involved. Micro RNAs (miRNAs) are a class of small RNAs that regulate many cellular pathways, including proliferation, survival, and differentiation. The objective of this study was to identify miRNAs downstream of PU.1 that regulate hematopoietic development. MATERIALS AND METHODS: miRNAs that change expression in a PU.1-inducible cell line were identified with microarrays. The promoter for an miRNA cluster upregulated by PU.1 induction was analyzed for PU.1 binding by electrophoretic mobility shift and chromatin immunoprecipitation assays. Retroviral transduction of hematopoietic progenitors was performed to evaluate the effect of miRNA expression on hematopoietic development in vitro and in vivo. RESULTS: We identified an miRNA cluster whose pri-transcript is regulated by PU.1. The pri-miRNA encodes three mature miRNAs: miR-23a, miR-27a, and miR-24-2. Each miRNA is more abundant in myeloid cells compared to lymphoid cells. When hematopoietic progenitors expressing the 23a cluster miRNAs were cultured in B-cell-promoting conditions, we observed a dramatic decrease in B lymphopoiesis and an increase in myelopoiesis compared to control cultures. In vivo, hematopoietic progenitors expressing the miR-23a cluster generate reduced numbers of B cells compared to control cells. CONCLUSIONS: The miR-23a cluster is a downstream target of PU.1 involved in antagonizing lymphoid cell fate acquisition. Although miRNAs have been identified downstream of PU.1 in mediating development of monocytes and granulocytes, the 23a cluster is the first downstream miRNA target implicated in regulating development of myeloid vs lymphoid cells.


Subject(s)
B-Lymphocytes/metabolism , Cell Differentiation/physiology , Gene Expression Regulation/physiology , Lymphopoiesis/physiology , MicroRNAs/biosynthesis , Proto-Oncogene Proteins/metabolism , Trans-Activators/metabolism , Animals , B-Lymphocytes/cytology , Cell Line , Hematopoietic Stem Cells , Mice , MicroRNAs/genetics , Myeloid Cells/cytology , Myeloid Cells/metabolism , Proto-Oncogene Proteins/genetics , Trans-Activators/genetics
5.
Blood ; 114(1): 60-3, 2009 Jul 02.
Article in English | MEDLINE | ID: mdl-19321862

ABSTRACT

In embryonic stem cells, Oct-4 concentration is critical in determining the development of endoderm, mesoderm, and trophectoderm. Although Oct-4 expression is essential for mesoderm development, it is unclear whether it has a role in the development of specific mesodermal tissues. In this study, we have examined the importance of Oct-4 in the generation of hematopoietic cells using an inducible Oct-4 ESC line. We demonstrate that Oct-4 has a role in supporting hematopoiesis after specifying brachyury-positive mesoderm. When we suppressed Oct-4 expression before or after mesoderm specification, no hematopoietic cells are detected. However, hematopoiesis can be rescued in the absence of Oct-4 after mesoderm specification if the essential hematopoietic transcription factor stem cell leukemia is expressed. Our results suggest that, for hematopoiesis to occur, Oct-4 is required for the initial specification of mesoderm and subsequently is required for the development of hematopoietic cells from uncommitted mesoderm.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/physiology , Embryonic Stem Cells/cytology , Embryonic Stem Cells/physiology , Hematopoiesis/physiology , Octamer Transcription Factor-3/deficiency , Proto-Oncogene Proteins/physiology , Animals , Basic Helix-Loop-Helix Transcription Factors/genetics , Cell Differentiation , Cell Line , Gene Expression Regulation, Developmental , Gene Silencing , Hematopoiesis/genetics , Mesoderm/embryology , Mesoderm/physiology , Mice , Octamer Transcription Factor-3/antagonists & inhibitors , Octamer Transcription Factor-3/genetics , Proto-Oncogene Proteins/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , T-Cell Acute Lymphocytic Leukemia Protein 1 , Transfection
6.
J Biol Chem ; 281(14): 9589-99, 2006 Apr 07.
Article in English | MEDLINE | ID: mdl-16434395

ABSTRACT

Tropomodulin-1 (Tmod-1) is a well defined actin-capping protein that interacts with tropomyosin (TM) at the pointed end of actin filaments. Previous studies by others have mapped its TM-binding domain to the amino terminus from amino acid 39 to 138. In this study, we have identified several amino acid residues on Tmod-1 that are important for its interaction with TM5 (a nonmuscle TM isoform). Glutathione S-transferase affinity chromatography and immunoprecipitation assays reveal that Tmod sense mutations of either amino acid 134, 135, or 136 causes various degrees of loss of function of Tmod TM-binding ability. The reduction of TM-binding ability was relatively mild (reduced approximately 20-40%) from the G136A Tmod mutant but more substantially (reduced approximately 50-100%) from the I134D, L135E, and L135V Tmod mutants. In addition, mutation at any of these three sites dramatically alters the subcellular location of Tmod-1 when introduced into mammalian cells. Further analysis of these three mutants uncovered a previously unknown nuclear trafficking function of Tmod-1, and residues 134, 135, and 136 are located within a nuclear export signal motif. As a result, mutation on either residue 134 or residue 135 not only will cause a significant reduction of the Tmod-1 ability to bind to TM5 but also lead to predominant nuclear localization of Tmod-1 by crippling its nuclear export mechanism. The failure of the Tmod mutations to fully associate with TM5 when introduced into neonatal rat cardiomyocytes was also associated with an accelerated and severe fragmentation of sarcomeric structures compared with overexpression of wild type Tmod-1. The multiple losses of function of Tmod engendered by these missense mutations are most severe with the single substitution of residue 135.


Subject(s)
Tropomodulin/genetics , Tropomodulin/metabolism , Tropomyosin/metabolism , Chromatography, Affinity , Gene Expression Profiling , Humans , Immunoprecipitation , Leucine , Mutagenesis , Mutation, Missense , Protein Binding , Protein Isoforms , Protein Structure, Tertiary , Sarcomeres , Tropomodulin/biosynthesis , Tropomodulin/chemistry , Two-Hybrid System Techniques , Yeasts
7.
Stem Cells ; 22(6): 981-93, 2004.
Article in English | MEDLINE | ID: mdl-15536189

ABSTRACT

Limb girdle muscular dystrophy type 2B form (LGMD-2B) and Miyoshi myopathy (MM) are both caused by mutations in the dysferlin (dysf) gene. In this study, we used dysferlin-deficient sjl mice as a mouse model to study cell therapy for LGMD-2B and MM. A single-blind study evaluated the therapeutic potential of human umbilical cord blood (HUCB) as a source of myogenic progenitor stem cells. Three groups of donor cells were used: unfractionated mononuclear HUCB cells, HUCB subfractionated to enrich for cells that were negative for lineage surface markers (LIN(-)) and substantially enriched for the CD34 surface marker (CD34(+)), and irradiated control spleen cells. We administrated 1 x 10(6) donor cells to each animal intravenously and euthanized them at different time points (1-12 weeks) after transplantation. All animals were immunosuppressed (FK506 and leflunomide) from the day before the injection until the time of euthanasia. Immunohistochemical analyses documented that a small number of human cells from the whole HUCB and LIN(-)CD34(+/-)-enriched HUCB subgroups engraft in the recipient muscle to express both dysferlin and human-specific dystrophin at 12 weeks after transplantation. We conclude that myogenic progenitor cells are present in the HUCB, that they can disseminate into muscle after intravenous administration, and that they are capable of myogenic differentiation in host muscle.


Subject(s)
Cell Culture Techniques/methods , Fetal Blood/cytology , Animals , Antigens, CD34/biosynthesis , CD4 Antigens/biosynthesis , CD8 Antigens/biosynthesis , Cell Differentiation , Cell Lineage , Cell Transplantation , Cellular Senescence , Dysferlin , Dystrophin/biosynthesis , Female , Humans , Immunohistochemistry , Immunosuppressive Agents/pharmacology , Isoxazoles/pharmacology , Kidney/metabolism , Leflunomide , Leukocytes, Mononuclear/cytology , Liver/metabolism , Membrane Proteins/biosynthesis , Mice , Muscle Proteins/biosynthesis , Spleen/cytology , Stem Cells/cytology , T-Lymphocytes/cytology , Tacrolimus/pharmacology , Time Factors
8.
J Biol Chem ; 279(29): 30856-64, 2004 Jul 16.
Article in English | MEDLINE | ID: mdl-15123707

ABSTRACT

Tropomodulin (Tmod) is a cytoskeletal actin-capping protein that interacts with tropomyosin at the pointed end of actin filaments. E-Tmod is an isoform that expresses predominantly in cardiac cells and slow skeletal muscle fibers. We unexpectedly discovered significant levels of Tmod in nuclei and then defined peptide domains in Tmod responsible for nuclear import and export. These domains resemble, and function as, a nuclear export signal (NES) and a pattern 4 nuclear localization signal (NLS). Both motifs are conserved in other Tmod isoforms and across species. Comparisons of wild-type Tmod and Tmod carrying mutations in these peptide domains revealed that Tmod normally traffics through the nucleus. These observations logically presuppose that Tmod functions may include a nuclear role. Indeed, increasing Tmod in the nucleus severely hampered myogenic differentiation and selectively suppressed muscle-specific gene expression (endogenous p21, myosin heavy chain, myogenin, and Tmod) but did not affect endogenous glyceraldehyde-3-phosphate dehydrogenase or expression from a transfected E-GFP vector. These results suggest that, at least in myogenic cells, nuclear Tmod may be involved in the differentiation process.


Subject(s)
Actins/chemistry , Carrier Proteins/metabolism , Cell Nucleus/metabolism , Cytoplasm/metabolism , Microfilament Proteins/metabolism , Active Transport, Cell Nucleus , Amino Acid Motifs , Animals , Blotting, Northern , Blotting, Western , Carrier Proteins/chemistry , Cell Differentiation , Cell Line , Cells, Cultured , Cytoskeleton/metabolism , Electrophoresis, Polyacrylamide Gel , Green Fluorescent Proteins , Lentivirus/genetics , Luminescent Proteins/metabolism , Mice , Mice, Inbred C3H , Microfilament Proteins/chemistry , Microscopy, Fluorescence , Microscopy, Phase-Contrast , Models, Genetic , Mutagenesis, Site-Directed , Mutation , Myocytes, Cardiac/cytology , Nuclear Localization Signals , Plasmids/metabolism , Protein Isoforms , Protein Structure, Tertiary , RNA/metabolism , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Recombinant Fusion Proteins/metabolism , Transfection , Tropomodulin
SELECTION OF CITATIONS
SEARCH DETAIL
...